Notably, the knockout of BCL9L by CRISPR/Cas9 resulted in the downregulation of β‐catenin expression at both the whole cell and nuclear levels in the soft tumor cells (Figs 5B and EV5E). The gene discussed is BCL9L; the disease is neoplasm.